Results 171 to 180 of about 118,357 (315)
Coronary artery aneurysms and myocardial infarction: adult sequelae of Kawasaki disease? [PDF]
Stephen Brecker +2 more
openalex +1 more source
What's new? Mitogen‐activated protein kinase (MAPK) inhibitors are promising treatments for pediatric Langerhans cell histiocytosis (LCH), a rare heterogeneous neoplasm that often affects multiple organ systems. Which MAPK inhibitors are most effective against LCH remains uncertain.
Xue Tang +5 more
wiley +1 more source
Humoral cross-coronavirus responses against the S2 region in children with Kawasaki disease
Ajit Monteiro +4 more
openalex +2 more sources
Boron Neutron Capture Therapy at a Crossroads: Translational Gap and Emerging Delivery Agents
This review surveys recent advances in boron delivery agents for BNCT, emphasizing the shift from classical small molecules to multifunctional nanocarriers and theranostic systems. By integrating targeting, imaging, and therapy, next‐generation boron compounds aim to bridge the gap between (bio)chemical innovation and clinical translation.
Christoph Selg, Evamarie Hey‐Hawkins
wiley +1 more source
CHOLESTASIS SYNDROME IN CHILDREN WITH KAWASAKI DISEASE [PDF]
Vaidotas Urbonas
openalex +1 more source
Kawasaki Disease Shock Syndrome vs Classical Kawasaki Disease: A Meta-analysis and Comparison With SARS-CoV-2 Multisystem Inflammatory Syndrome [PDF]
Loubna Lamrani +8 more
openalex +1 more source
Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li +10 more
wiley +1 more source
Electroencephalography signals and neurodevelopment after Kawasaki disease: A pilot study [PDF]
Audrey‐Ann Fauteux +7 more
openalex +1 more source
Abstract This work presents the optimization of cell cultivation for monoclonal antibody (mAb) production. We developed a hybrid model describing the effects of multiple process variables on antibody productivity and impurity generation. An automated platform with 12 × 250 mL bioreactors was set up.
Kosuke Nemoto +6 more
wiley +1 more source

